← Human Trials & Peer-Reviewed Studies
Blockade of Angiotensin II Receptor Type 1 Abolishes the Erythropoietin Response to Exercise.
Plain-language guide to PMID 40690272 (2025): double-blind randomized controlled trial of Angiotensin II.
Key Facts
- PMID
- 40690272
- Journal
- Function (Oxford, England)
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Guo M et al. (2 authors)
- DOI
- 10.1093/function/zqaf032
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Angiotensin II, published as a randomized controlled trial.
Whether commonly prescribed antihypertensive medication inhibits erythropoietin (EPO) production with exercise, a key response to enhance aerobic capacity, remains unknown.
Before and after 1 h of moderate cycling exercise, blood samples were taken to measure circulating EPO and EPO-regulating hormones along with blood pressure.
Who Took Part
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and crossover study.
Random assignment meant chance, not the researchers, decided who got Angiotensin II and who got the comparison, which limits bias.
As a double-blind Angiotensin II study, the assignments were hidden from both participants and investigators until the end.
Some participants received a placebo instead of Angiotensin II, giving a reference point.
Each person switched between Angiotensin II and the comparison at some point, usually with a gap in between.
Cardiac structure/function and peak pulmonary O2 consumption (VO2peak) were assessed during exercise.
What Was Measured
Before and after 1 h of moderate cycling exercise, blood samples were taken to measure circulating EPO and EPO-regulating hormones along with blood pressure.
PubMed files the paper under topics including Erythropoietin, Exercise, Angiotensin II Type 1 Receptor Blockers, Valsartan, Oxygen Consumption, Blood Pressure and Receptor, Angiotensin, Type 1.
Author keywords: antihypertensive medication, exercise-induced erythropoiesis, randomized controlled trial and renin-angiotensin system.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II.
The publication is from 2025 (Function (Oxford, England)), a journal based in United States.
More context: the Angiotensin II compound page, all human trials.
Our Notes on the Compound
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.